Is BPC-157 legal? FDA status, evidence and risks (October 2026)

Status at a glance

What BPC-157 is, and what it is sold for

BPC-157 is a synthetic peptide. Clinics and online sellers market it for tendon, muscle and joint recovery and for gut problems. When FDA’s advisory committee looked at it in July 2026, the use put forward by the nominator was ulcerative colitis, and FDA evaluated it for that use only.

Human evidence

FDA staff reviewed the available data for the July 2026 meeting and concluded: “Accordingly, we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List” (FDA briefing). The committee then voted the other way, narrowly, which tells you the evidence is contested rather than settled.

We did not find adequate, controlled human trials showing that BPC-157 heals tendons, muscle or the gut, and we have not re-read the clinical literature for this update, so we cite no human study. If a seller quotes one, ask whether it was controlled and how many people took part.

Animal and laboratory evidence

Most published research on BPC-157 is preclinical: animal and cell studies, the source of most marketing claims. Animal healing models often fail to predict results in people, so we do not present any animal result as a human benefit.

Risks

FDA’s own safety summary says compounded BPC-157 “may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization” (FDA). In plain terms: your immune system may react to it, and it is hard to confirm that a vial contains what the label says and nothing else.

Research-website products add more unknowns: no prescription, no named pharmacy and no sterility testing you can check. Long-term safety in people has not been established.

Legal sourcing: who can supply it

Because BPC-157 is not FDA-approved, not on the 503A bulks list and not in Category 1, a licensed U.S. pharmacy has no established federal route to compound it for you as of October 15, 2026. A clinic that prescribes it is relying on a pathway FDA has not recognised. See our peptide legality guide for the routes that do exist.

The lawful route for a prescription peptide in the United States is a licensed clinician who examines you and writes a prescription, filled by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility that is allowed to use that substance. Websites that sell peptides “for research use only” or “not for human consumption” are not a lawful source of medicine for people. On August 24, 2026, FDA sent warning letters to five such sellers — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides — calling their products unapproved new drugs. FDA wrote that the research-use labels did not change its view because the websites showed the products were meant for human use.

October 2026: what changed

• April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
• July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
• October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.

For BPC-157: it is the peptide most often named in coverage of the interim policy, but its status is unchanged until a policy is published. Treat any clinic claiming BPC-157 is “now legal” as ahead of the facts. Updates: our research vs prescription peptides page and in the peptide hub.

New this month: what is known about FDA’s peptide interim access policy · a status table for 16 peptides (FDA and WADA).